Gemina Laboratories Company Description

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada.

The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test.

It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

Gemina Laboratories Ltd.

Country	Canada
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Brian Firth

Contact Details

Address: 3600 Gilmore Way Burnaby, British Columbia V5G 4W8 Canada
Website	geminalabs.com

Stock Details

Ticker Symbol	GLAB
Exchange	Canadian Securities Exchange
Fiscal Year	February - January
Reporting Currency	CAD
ISIN Number	CA3686501071
SIC Code	6722

Key Executives

Name	Position
Brian Firth	Chief Executive Officer and Director
Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA	Chief Financial Officer and Company Secretary
Dr. Robert Crandall Greene	Chief Technology Officer and Director
Hugh McNaught	Vice President of Marketing and Member of Advisory Board
David Browning FCIM, M.Sc.	Head of Productization and Director of Gemina Laboratories (UK) Limited
Dr. Christine Buerki Ph.D.	Head of Product Development